



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Jamila Mammadova  
jmammadova@usf.edu

SPECIALTY SECTION  
This article was submitted to  
Pharmacology of Anti-Cancer Drugs,  
a section of the journal  
Frontiers in Oncology

RECEIVED 30 July 2022  
ACCEPTED 17 August 2022  
PUBLISHED 22 September 2022

CITATION  
Mammadova J, Redden A, Cruz R,  
Ujhazi B, Gordon S, Ellison M,  
Gatewood T, Duff C, Cannella A,  
Somboonwit C, Sriaroon C, Csomos K,  
Dasso JF, Harville T, Ismail-Khan R and  
Walter JE (2022) Corrigendum:  
Case report: Initial treatment  
adjustments and complications in  
ovarian cancer patient with inborn  
error of immunity.  
*Front. Oncol.* 12:1007616.  
doi: 10.3389/fonc.2022.1007616

COPYRIGHT  
© 2022 Mammadova, Redden, Cruz,  
Ujhazi, Gordon, Ellison, Gatewood, Duff,  
Cannella, Somboonwit, Sriaroon,  
Csomos, Dasso, Harville, Ismail-Khan  
and Walter. This is an open-access  
article distributed under the terms of  
the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution  
or reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Corrigendum: Case report: Initial treatment adjustments and complications in ovarian cancer patient with inborn error of immunity

Jamila Mammadova<sup>1\*</sup>, Anna Redden<sup>2</sup>, Rachel Cruz<sup>1</sup>,  
Boglarka Ujhazi<sup>3</sup>, Sumai Gordon<sup>3</sup>, Maryssa Ellison<sup>3</sup>,  
Tyra Gatewood<sup>4</sup>, Carla Duff<sup>3</sup>, Anthony Cannella<sup>5</sup>,  
Charurut Somboonwit<sup>5</sup>, Chakrapol Sriaroon<sup>5</sup>,  
Krisztian Csomos<sup>3</sup>, Joseph F. Dasso<sup>3</sup>, Terry Harville<sup>6</sup>,  
Roohi Ismail-Khan<sup>7</sup> and Jolan E. Walter<sup>3</sup>

<sup>1</sup>Morsani College of Medicine, University of South Florida, Tampa, FL, United States, <sup>2</sup>Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, United States, <sup>3</sup>Division of Allergy and Immunology, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, United States, <sup>4</sup>Department of Pharmacy at Gynecologic and Neuro Oncology Clinics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States, <sup>5</sup>Division of Infectious Disease and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, United States, <sup>6</sup>Division of Hematology, Department of Pathology and Laboratory Services, and Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States, <sup>7</sup>Department of Cardio-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

## KEYWORDS

antibody deficiency, primary immunodeficiency, ovarian cancer, case report, inborn error of immunity

## A corrigendum on

**Case report: Initial treatment adjustments and complications in ovarian cancer patient with inborn error of immunity**

by Mammadova J, Redden A, Cruz R, Ujhazi B, Gordon S, Ellison M, Gatewood T, Duff C, Cannella A, Somboonwit C, Sriaroon C, Csomos K, Dasso JF, Harville T, Ismail-Khan R and Walter JE (2022) *Front. Oncol.* 12:843741. doi: 10.3389/fonc.2022.843741

In the published article, there was an error in the author list, and authors Boglarka Ujhazi, Sumai Gordon, and Krisztian Csomos were erroneously excluded. In addition, their author contributions statement has been updated. The corrected statement reads as follows:

JM - manuscript write up, data collection, patient interview. AR - manuscript write up, literature review. RC - manuscript write up. ME - clinical research coordination. TG - pharmacy in gynecology clinic. CD, KC, BU, and SG - immunologic evaluation. AC - control of infectious diseases. CSo - control of infectious diseases. CSr - control of pulmonary infections. JD - manuscript write up, immunologic evaluation, literature review. TH - early treating immunologist, primary diagnosis with IEL. RI-K - treating oncologist. JW - currently treating immunologist, primary investigator. All authors contributed to the article and approved the submitted version.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.